血清生物标志物预测慢性病毒性肝炎患者纤维化的表现。

StephenW

Korean J Gastroenterol. 2017 May 25;69(5):298-307. doi: 10.4166/kjg.2017.69.5.298.
The Performance of Serum Biomarkers for Predicting Fibrosis in Patients with Chronic Viral Hepatitis.
Bang CS1, Kang HY2, Choi GH2, Kim SB2, Lee W3, Song IH2.
Author information

1    Department of Internal Medicine, Hallym University College of Medicine, Dankook University College of Medicine, Cheonan, Korea.
2    Department of Internal Medicine, Dankook University College of Medicine, Cheonan, Korea.
3    Department of Pathology, Dankook University College of Medicine, Cheonan, Korea.

Abstract
Background/Aims:

The invasiveness of a liver biopsy and its inconsistent results have prompted efforts to develop noninvasive tools to evaluate the severity of chronic hepatitis. This study was intended to assess the performance of serum biomarkers for predicting liver fibrosis in patients with chronic viral hepatitis.
Methods:

A total of 302 patients with chronic hepatitis B or C, who had undergone liver biopsy, were retrospectively enrolled. We investigated the diagnostic accuracy of several clinical factors for predicting advanced fibrosis (F≥3).
Results:

The study population included 227 patients with chronic hepatitis B, 73 patients with chronic hepatitis C, and 2 patients with co-infection (hepatitis B and C). Histological cirrhosis was identified in 16.2% of the study population. The grade of porto-periportal activity was more correlated with the stage of chronic hepatitis compared with that of lobular activity (r=0.640 vs. r=0.171). Fibrosis stage was correlated with platelet count (r=-0.520), aspartate aminotransferase to platelet ratio index (APRI) (r=0.390), prothrombin time (r=0.376), and albumin (r=-0.357). For the diagnosis of advanced fibrosis, platelet count and APRI were the most predictive variables (AUROC=0.752, and 0.713, respectively).
Conclusions:

In a hepatitis B endemic region, platelet count and APRI could be considered as reliable non-invasive markers for predicting fibrosis of chronic viral hepatitis. However, it is necessary to validate the diagnostic accuracy of these markers in another population.
KEYWORDS:

Biopsy; Chronic hepatitis; Liver fibrosis

PMID:
    28539035
DOI:
    10.4166/kjg.2017.69.5.298

StephenW

韩国J胃肠病。 2017年5月25日; 69（5）：298-307。 doi：10.4166 / kjg.2017.69.5.298。
血清生物标志物预测慢性病毒性肝炎患者纤维化的表现。
Bang CS1，Kang HY2，Choi GH2，Kim SB2，Lee W3，Song IH2。
作者信息

1韩国天安大学医学院哈利姆大学医学院内分泌科。
2韩国天安大学医学院内分泌科。
韩国天安大学医学院病理科3。

抽象
背景/目的：

肝活检的侵袭及其不一致的结果促使开发非侵入性工具来评估慢性肝炎的严重程度。本研究旨在评估慢性病毒性肝炎患者血清生物标志物预测肝纤维化的表现。
方法：

回顾性分析了302例慢性乙型肝炎或丙型肝炎患者，接受肝活检。我们调查了预测晚期纤维化（F≥3）的几个临床因素的诊断准确性。
结果：

研究人群包括227例慢性乙型肝炎患者，73例慢性丙型肝炎患者和2例共感染（乙型和丙型肝炎）患者。 16.2％的研究人群中发现组织学肝硬化。与小叶活动相比，门静脉周围活动程度与慢性肝炎相关性更高（r = 0.640，r = 0.171）。纤维化阶段与血小板计数（r = -0.520），天冬氨酸氨基转移酶与血小板比指数（APRI）（r = 0.390），凝血酶原时间（r = 0.376）和白蛋白（r = -0.357）相关。对于晚期纤维化的诊断，血小板计数和APRI是最具预测性的变量（AUROC = 0.752，分别为0.713）。
结论：

在乙肝特有区域，血小板计数和APRI可被认为是预测慢性病毒性肝炎纤维化的可靠非侵入性标记物。然而，有必要验证这些标记在另一群体中的诊断准确性。
关键词：

活检;慢性肝炎肝纤维化

结论：
    28539035
DOI：
    10.4166 / kjg.2017.69.5.298